1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
Medicago/GSK’s COVID-19 Vaccine 71% Effective: PII/III
A plant-derived COVID-19 vaccine being developed by Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, using GlaxoSmithKline’s pandemic adjuvant was 71% effective against multiple variants in a placebo-controlled PII/III study, the companies said on December 7. The companies confirmed the…
To read the full story
Related Article
- Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
- Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
- Medicago Submits Final Vaccine Data for Canada’s COVID-19 Rolling Review
December 20, 2021
- Mitsubishi to Mull Domestic Manufacturing of COVID-19 Vaccine: Exec
November 4, 2021
- Medicago’s COVID-19 Vaccine Yields Positive Interim Data: PII
May 20, 2021
- Canada Starts Review of Medicago’s Rolling Submission for COVID-19 Vaccine
April 27, 2021
- Medicago/GSK Begins PIII for COVID-19 Vaccine, Mitsubishi Mum on Japan Plan
March 18, 2021
BUSINESS
- AstraZeneca Rolling Out “Unify” App for Decentralized Trials in Japan
February 27, 2025
- Daiichi Eyes 9 New Indications for 2 Lead ADCs, Tripling Patient Number by 2026
February 27, 2025
- Kissei Files Linzagolix for Uterine Fibroids in Japan
February 27, 2025
- Lilly Japan Fostering Better Understanding of Health Issues to Retain Female Reps
February 26, 2025
- Seikagaku Kicks Off Japan PIII for Osteoarthritis Drug Gel-One
February 26, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…